important that we generate more growth with less risk." GSK needs to find new sources of growth at a time when governments around the world are reforming healthcare and cutting spending. It is also outsourcing more research to partners to reduce risk. Its long-running collaboration with the US company‚ Theravance which is responsible for one of GSK ’s most promising new drugs‚ the asthma treatment Relovair‚ which is now in late-stage development. GSK recently upped its stake in Theravance to 19% and this
Premium Clinical trial Strategic management Pharmacology
GSK Marketing Planning | March 31 2013 | Calvin Cheung‚ Hussain Al Katib‚ Manpreet Budwal‚ Sandra Okechukwu | SOSTAC Review based on GlaxoSmithKline | Content Table of Contents 1.0 Introduction2 2.0 Situation Analysis3 2.1 PESTEL Analysis3 2.2 SWOT Analysis4 2.3 Boston Matrix5 2.4 Porter’s Five Forces Analysis6 3.0 Objectives8 4.0 Strategy9 4.1 Product9 4.2 Price9 4.3 Promotion9 4.4 Place10 4.5 Person10 4.6 Process10 4.7 Physical Evidence10 5.0 Tactics11 6.0 Action Plan12
Premium Marketing
Introduction Based on a report conducted by a pharmaceutical magazine‚ Glaxosmithkline plc (Also known as GSK) is the fifth largest pharmaceutical company around the world (Contract Pharma‚ 2013). And it is also tided at No.112 on the 2013 ’s Global 2000 list‚ the list that manifests the 2000 most enormous companies in the world (Forbes‚ 2013). The researches above have indicated that GSK is one of the largest Transnational Corporation in the world. Top 10 Pharmaceutical Companies based on 2012
Premium Strategic management Pharmaceutical industry
Answer 2 …… Glaxosmithkline (GSK )‚ a research and development firm seeking to be excel in internal innovation through research on eight therapy areas- biopharmaceuticals‚ immune-inflammation‚ infectious diseases‚ metabolic pathways‚ neuroscience‚ oncology‚ ophthalmology and respiratory. To address these areas the firm in 2008 created 70 Discovery Performance Unit (DPUs) for future growth of the company. These 70 DPUs can affect the implementation effort in following ways to achieve success in
Premium Research Control theory Innovation
Drug discovery is a process in medicine and pharmacology where a drug is discovered and designed. In the past drug discovery was very different to the current form‚ previously active ingredients were used to tackle illnesses. Nowadays more detailed research on diseases has been pursued‚ details such as what the genes are coding or what protein is involved‚ therefore are allowing the designing of drugs to target specific sites to act on the disease. Once detailed information of the disease has been
Premium Pharmacology Clinical trial
CASE STUDY Presentation Outline: Background Case Summary What is ‘crisis management’? Strategic Phase Reactive Phase Image Restoration Lessons Learnt Background: GlaxoSmithKline (GSK) is a British multinational pharmaceutical and consumer healthcare company that operates in over 100 countries. They have an extensive portfolio of products for major disease areas including asthma‚ cancer‚ infection‚ diabetes and digestive conditions Some products they produce that you might be familiar
Free Crisis management Management
1) Product markets and geographic markets in which GSK is present GSK’s core mission is to “improve the quality of human life by enabling people to do more‚ feel better and live longer”. To achieve this mission‚ they operate in three main areas of businesses: the Pharmaceuticals (£18 Bn in 2012‚ or 68% of their revenues)‚ the Vaccines (£3.3 Bn‚ or 11% or their revenues) and the Consumer Healthcare (£5.1 Bn‚ or 19% of their revenues). In particular‚ the Pharmaceuticals cover medicines to treat a broad
Premium Medicine Pharmacology Food and Drug Administration
name] GSK – Successful Internal Innovation Question 1 Based on GSK’s past performance‚ what do you believe are the critical implementation issues for GSK with regards to internal innovation? Figure 4‚ 2‚ pg 132‚ The management of technology and innovation (White & Brighton) GSK key reason of success lies in its continuous radical change‚ by constantly inventing new drugs. Critical to the implementation issues of its internal innovation are raised below: Leadership GSK leadership
Premium Control system Control engineering Invention
Case study C: GSK‚ a merger too far? 1- Derive three opportunities and three threats for GSK by first making the PESTEL analysis of the macro-environment surrounding the pharmaceutical industry. (9 points) * PESTEL analysis of the pharmaceutical industry: Political: Since the creation of healthcare insurance‚ companies have to conform themselves to two kinds of systems: 1) The universal system applied for example in France‚ with less demand in new technologies. 2) The very selective anglo-saxon
Premium Pharmacology Generic drug Pharmaceutical industry
Financial statements P102–P191 Shareholder information P192–P212 Business review 2010 Performance overview Research and development Pipeline summary Products‚ competition and intellectual property Regulation Manufacturing and supply World market GSK sales performance Segment reviews Responsible business Financial review 2010 Financial position and resources Financial review 2009 Risk factors Governance and remuneration Our Board Our Corporate Executive Team Governance and policy Dialogue with shareholders
Premium Vaccine Rate of return Clinical trial